GH Research PLC (NASDAQ:GHRS – Get Free Report) saw a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,300,000 shares, a drop of 5.8% from the July 31st total of 1,380,000 shares. Approximately 4.9% of the shares of the company are sold short. Based on an average trading volume of 74,200 shares, the short-interest ratio is currently 17.5 days.
GH Research Stock Down 2.0 %
Shares of NASDAQ GHRS opened at $10.42 on Friday. GH Research has a 52 week low of $5.70 and a 52 week high of $16.71. The firm has a 50-day moving average price of $12.16 and a 200 day moving average price of $10.52. The stock has a market capitalization of $526.42 million, a price-to-earnings ratio of -15.10 and a beta of 0.80.
GH Research (NASDAQ:GHRS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 23rd. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. Equities research analysts expect that GH Research will post -1.06 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Hedge Funds Weigh In On GH Research
Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in GH Research by 13,760.0% during the 4th quarter. Bank of America Corp DE now owns 2,772 shares of the company’s stock valued at $27,000 after acquiring an additional 2,752 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in GH Research by 246.2% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,075 shares of the company’s stock valued at $33,000 after acquiring an additional 2,898 shares in the last quarter. Renaissance Technologies LLC purchased a new position in GH Research during the 1st quarter valued at about $86,000. State Street Corp purchased a new position in GH Research during the 3rd quarter valued at about $127,000. Finally, Bank of Montreal Can purchased a new position in GH Research during the 2nd quarter valued at about $133,000.
GH Research Company Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.
- Five stocks we like better than GH Research
- 5 Top Rated Dividend Stocks to Consider
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Trading Stocks: RSI and Why it’s Useful
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- What Does a Stock Split Mean?
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.